Table 5 Perceived influence of product strategy on physicians’ prescribing behavior in hospitals of Dessie, Ethiopia (n = 136)
No. | Description | SDa N (%) | Da N (%) | Na N (%) | Aa N (%) | SAa N (%) | Mean ± SD |
|---|---|---|---|---|---|---|---|
1 | Country of pharmaceutical product manufacturer | 6 (4.4) | 14 (10.3) | 36 (26.5) | 52 (38.2) | 28 (20.6) | 3.60 ± 1.06 |
2 | Image of pharmaceutical company | 4 (2.9) | 24 (17.6) | 33 (24.4) | 49 (36) | 26 (19.1) | 3.51 ± 1.08 |
3 | Supportive evidence of the efficacy of the medicine given by pharmaceutical company | 0 (0) | 10 (7.4) | 20 (14.6) | 64 (47.1) | 42 (30.9) | 4.01 ± 0.86 |
4 | Release of new innovations or combinations of drugs | 1 (0.7) | 12 (8.8) | 17 (12.6) | 52 (38.2) | 54 (39.7) | 4.07 ± 0.97 |
5 | Form of delivery of the medicine | 1 (0.7) | 15 (11) | 20 (14.7) | 64 (47.1) | 36 (26.5) | 3.88 ± 0.95 |
6 | Easy to remember brand names | 9 (6.6) | 22 (16.2) | 31 (22.8) | 55 (40.4) | 19 (14) | 3.39 ± 1.11 |
7 | Reputation of the source of medicine | 9 (6.6) | 16 (11.8) | 42 (30.8) | 50 (36.8) | 19 (14) | 3.40 ± 1.07 |
8 | Quality of medicine | 2 (1.5) | 11 (8.1) | 13 (9.5) | 53 (39) | 57 (41.9) | 4.12 ± 0.98 |
9 | Fixed-dose packaging of the product | 5 (3.7) | 18 (13.2) | 21 (15.5) | 52 (38.2) | 40 (29.4) | 3.76 ± 1.12 |
10 | Full therapy packaging | 8 (5.9) | 24 (17.6) | 26 (19.1) | 51 (37.5) | 27 (19.9) | 3.48 ± 1.16 |